Cytoplasmic ANCA (c-ANCA), perinuclear ANCA (p-ANCA), atypical ANCA, anti-myeloperoxidase (anti-MPO) or anti-proteinase-3 (anti-PR3). Logistic or linear regression were used to determine ...

In this retrospective study, the cytoplasmic ANCA (cANCA) positivity status and anti-proteinase-3 (PR3)-ANCA ... became and stayed negative for cANCA (P = 0.01) or PR3-ANCA (P = 0.02) until ...

This can visualize patterns which are either cytoplasmic, and are designated as c-ANCA, or perinuclear, designated as p-ANCA. C-ANCA is now called proteinase-3 ANCA (PR3-ANCA), and p-ANCA is ...

We conducted a randomized trial with a 2-by-2 factorial design to evaluate the use of plasma exchange and two regimens of oral glucocorticoids in patients with severe ANCA ... 1.13; P=0.27).

71 ml per minute, P=0.01) (Table 1). Disease Relapses as Related to B-Cell Detectability and ANCA Of the 76 patients in the rituximab group and the 70 patients in the cyclophosphamide ...

GlaxoSmithKline is also making strides with its immunomodulatory drug portfolio and ongoing research into novel anti-inflammatory agents for autoimmune conditions such as ANCA-V. Pfizer and ...

DUBLIN--(BUSINESS WIRE)--The "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2018" clinical trials has been added to ...

GlaxoSmithKline is also making strides with its immunomodulatory drug portfolio and ongoing research into novel anti-inflammatory agents for autoimmune conditions such as ANCA-V. Pfizer and ...